Successful treatment tactics for a patient with non-alcoholic fatty liver disease and comorbid states

Non-alcoholic fatty liver disease (NAFLD) can be called the silent pandemic of the 21st century. The prevalence of this disease is progressively increasing worldwide, affecting an increasing number of people of working age, mainly in developed countries, negatively affecting the health of the population. Considering the fact that the pathogenesis of NAFLD is primarily associated with metabolic disorders and changes in glucose-insulin homeostasis, steatohepatosis is an independent risk factor for the development of type 2 diabetes mellitus and its complications, cardiovascular diseases and cardiovascular mortality due to progressive atherosclerosis. Treatment of NAFLD includes two main goals: prevention of disease progression, which consists in regression of steatosis, prevention of steatohepatitis and subsequent fibrosis, as well as active intervention in the development of metabolic disorders leading to the formation of cardiometabolic risks. The clinical case we presented demonstrates the need for an interdisciplinary approach to managing patients with metabolic syndrome to minimize the risks of development and progression of comorbid pathology.